American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

Pfizer close to acquiring Metsera for $7.3B, targeting breakthrough obesity drug

by admin September 22, 2025
September 22, 2025
Pfizer close to acquiring Metsera for $7.3B, targeting breakthrough obesity drug

Pfizer is making a bold move in the pharmaceutical world by closing in on a $7.3 billion deal to acquire Metsera, a biotech firm focused on next-generation anti-obesity drugs, news platform Financial Times reported on Monday.

This acquisition underlines Pfizer’s fresh push into the booming weight-loss drug market, an area showing rapid growth as obesity rates climb worldwide.

After facing challenges with its own weight loss drug programs, Pfizer sees this as a strategic way to strengthen its portfolio and join the race against established leaders in obesity treatments.

Pfizer eyes Metsera obesity breakthrough

The deal offers Metsera shareholders $47.50 per share in cash, with an additional $22.50 per share payable if certain performance targets are hit.

This premium of about 42% over Metsera’s recent share price reflects Pfizer’s eagerness to secure the promising biotech.

Metsera, based in New York and founded in 2022, has been developing innovative obesity treatments primarily through GLP-1 receptor agonists.

Its standout drug candidate, MET-097i, is designed to be injected once a month and has shown an average weight loss of 11.3% in mid-stage clinical trials, a major convenience leap compared to the weekly injections offered by Pfizer’s competitors.

Pfizer’s acquisition would be a sharp turnaround after it halted its own oral GLP-1 drug development earlier this year due to safety issues.

The deal, expected to be announced soon pending final talks, gives Pfizer access to Metsera’s pipeline, which includes potential combination therapies, positioning the company well in the obesity treatment space.

This payment structure, blending cash upfront with milestone incentives, aligns costs with drug development success, lowering some risk for Pfizer while aiming for high rewards.

Obesity drug race heats up

Pfizer’s move is a clear sign of how hot the obesity drug market has become, dominated until now by giants like Novo Nordisk and Eli Lilly.

These firms have scored major wins with GLP-1 therapies enabling significant weight loss, but Pfizer sees an opportunity with Metsera’s once-monthly dosing, which could attract patients looking for easier treatment options and improve drug adherence.

This deal highlights the trend of big pharma companies aggressively buying into promising biotech startups to keep pace with innovation rather than relying solely on internal development.

The acquisition also raises the stakes, as the anti-obesity market is forecasted to explode to nearly $100 billion by 2030, driven by demand for more effective, patient-friendly treatments.

While milestone-based payments introduce risk if Metsera’s drugs fall short in trials, Pfizer’s bet signals confidence in this expanding field.

The acquisition is poised to intensify competition and could spark more deals and technological advances, as companies race to capture a share of the lucrative, fast-evolving obesity drug market.

Ultimately, Pfizer’s bold purchase aims to place it among the leaders challenging the current duopoly and addressing a critical global health issue.

The post Pfizer close to acquiring Metsera for $7.3B, targeting breakthrough obesity drug appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Will Rolls-Royce share price hit 1,250p as Goldman Sachs predicts?
next post
Snap stock price forecast as the OS 2.0 upgrade rally gains steam

Related Posts

Top 4 Nasdaq 100 Index and QQQ ETF...

August 24, 2025

Starbucks China bids reportedly value biz at $10...

July 9, 2025

Tesla’s China sales edge up 0.8% in June;...

July 2, 2025

Top catalysts for the Nikkei 225 Index this...

July 27, 2025

Workday stock price: could WDAY hit $300 after...

November 24, 2024

WBD stock analysis: Warner Bros may surge 140%...

February 24, 2025

IRS announces Direct File as permanent free tax-filing...

June 1, 2024

Robinhood launches high-risk margin trading in UK following...

October 21, 2024

Constellation Energy stock surged: brace for a pullback

September 23, 2024

S&P 500 climbs for best day since early...

July 24, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Europe bulletin: Manchester synagogue attack aftermath, stocks close higher

      October 5, 2025
    • Evening digest: Trump sets deadline for Hamas, Canada’s slowdown, BTC rebounds

      October 5, 2025
    • Iran executes six people for alleged links to Israel, state media reports

      October 5, 2025
    • US digest: Trump’s Hamas ultimatum, government shutdown stalemate continues

      October 5, 2025
    • Japanese stocks may extend record run as Takaichi win revives ‘Abenomics’

      October 5, 2025

    Categories

    • Business (4,191)
    • Investing (2,958)
    • Latest News (2,080)
    • Politics (1,536)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved